A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors — Stella

Home/Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Peking University First Hospital, Beijing, Beijing Municipality

Key details

Phase

Early testing

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Enrollment target

~60 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years – 80 Years

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.